CD274 and endometrial cancer: Due to the high frequency of microsatellite instability and elevated mutational burden, subtypes of endometrial cancers are immunogenic, and immune checkpoint blockade against the PD-1/PD-L1 axis has been explored as a viable therapeutic option [23,26].